Oracle and Cognizant Aim to Accelerate Study Startup in Trials
Cognizant’s Shared Investigator Platform (SIP) has integrated with Oracle Health Sciences. Cognizant and Oracle have combined the SIP solution and study startup offerings to address site challenges and aim to deliver value in the initialization of studies, collaboration, and management.
“Being able to stay connected, reduce administrative work, and stand-up clinical trials quickly is paramount, especially as the world faces the pandemic and must maneuver around social distancing guidelines,” said Srinivas Shankar, Global Head of Life Sciences, Cognizant. “Since 2016, Cognizant’s Shared Investigator Platform has over 130,000 users across 100 countries. This digital solution, in collaboration with Oracle, is helping bridge digital technology and life sciences.”
For more information, click here.
Unifying Industry to Better Understand GCP Guidance
May 7th 2025In this episode of the Applied Clinical Trials Podcast, David Nickerson, head of clinical quality management at EMD Serono; and Arlene Lee, director of product management, data quality & risk management solutions at Medidata, discuss the newest ICH E6(R3) GCP guidelines as well as how TransCelerate and ACRO have partnered to help stakeholders better acclimate to these guidelines.
Phase III PROMINENT Trial Initiated to Evaluate Felzartamab for Primary Membranous Nephropathy
June 30th 2025The global Phase III PROMINENT trial has begun dosing patients to evaluate felzartamab in treating primary membranous nephropathy, a serious autoimmune kidney disorder with no FDA-approved therapies.
